Aug 13, 2020
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Jun 17, 2020
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 09, 2020
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
May 18, 2020
Akcea Announces Appointment of New Chief Financial Officer
May 07, 2020
Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
Apr 20, 2020
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Apr 14, 2020
n-Lorem Foundation receives $500,000 donation for providing experimental antisense medicines to treat patients with ultra-rare diseases
Mar 12, 2020
n-Lorem Foundation receives additional support for providing "n of 1" experimental antisense medicines to treat patients with ultra-rare diseases
Jan 22, 2020
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 09, 2020
Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Jan 08, 2020
n-Lorem Foundation established to charitably provide antisense medicines to treat patients with ultra-rare diseases
Jan 07, 2020
Ionis' neurological franchise marks year of achievement
Oct 28, 2019
Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
Oct 22, 2019
Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
Oct 10, 2019
Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
Oct 09, 2019
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Sep 11, 2019
Dynacure to Present at Chardan's 3rd Annual Genetic Medicines Conference
Aug 27, 2019
Ionis licenses hepatitis B program to GSK
Jul 30, 2019
Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
Jul 09, 2019
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Huntington's Disease